Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection

NCT04614012 is registered in ClinicalTrials.gov with ANNA FALANGA as lead sponsor.

NCT NCT04614012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection
Lead sponsor
ANNA FALANGA
Phase
Not applicable
Overall status
Unknown status
Start date
July 2, 2020
Completion date
July 2, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19